Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MERZEE vs ATROPINE AND DEMEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Short-term adjunctive therapy in the management of exogenous obesity,Off-label: weight loss maintenance
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 60 hours in severe impairment).
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Primarily hepatic via N-demethylation and other oxidative pathways; metabolites include amphetamine and methamphetamine.
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; biliary/fecal elimination accounts for about 25%, with the remainder as metabolites.
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
98% bound to serum albumin.
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
0.15 L/kg, indicating limited extravascular distribution (primarily confined to plasma and interstitial fluid).
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Oral bioavailability: 45-55% (first-pass metabolism). Not applicable for intravenous route.
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
GFR 30-89 m L/min: 300 mg twice daily; GFR <30 m L/min or on hemodialysis: 300 mg once daily.
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
Child-Pugh Class A: no adjustment; Class B: 300 mg twice daily; Class C: not recommended.
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Not approved for use in pediatric patients.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
Consider lower initial dose (300 mg twice daily) due to age-related renal impairment; monitor for cognitive effects.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
MERZEE has a high potential for abuse and dependence. Use in patients with a history of drug abuse or alcoholism is not recommended. Administration for extended periods may lead to drug dependence and must be avoided.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Risk of abuse and dependence; monitor for signs of abuse. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or anxiety states. Discontinue if tolerance develops. May impair ability to drive or operate machinery. Do not use with MAOIs or within 14 days of their discontinuation.
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
Hypersensitivity to benzphetamine or other sympathomimetics; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days of MAOI use; pregnancy; lactation.
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
High-fat meals reduce peak concentration (Cmax) by 28% and delay time to peak concentration (Tmax) by 2 hours. Grapefruit juice may increase perampanel levels via CYP3A4 inhibition; consider monitoring for side effects if consumed regularly. Alcohol and CNS depressants (e.g., benzodiazepines, opioids) may potentiate dizziness and sedation.
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimesters: no specific risk identified but limited data.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
No human data on excretion in breast milk; M/P ratio unknown. Risk to infant cannot be excluded. Use caution, considering importance of drug to mother.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
No established dose adjustments due to lack of pharmacokinetic data in pregnancy. Clinical monitoring advised for efficacy and toxicity.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
MERZEE (perampanel) is a selective non-competitive AMPA receptor antagonist. Monitor for neuropsychiatric symptoms including hostility, aggression, and suicidal ideation, especially in patients with a history of psychiatric disorders. Due to its long half-life (~105 hours in steady state), dose adjustments should be made at intervals of at least 2 weeks. Avoid use in severe hepatic impairment (Child-Pugh C); dose reduction required for mild to moderate impairment. Contraception counseling is essential for women of childbearing potential as perampanel decreases efficacy of oral contraceptives containing levonorgestrel. Potent CYP3A4 inducers (e.g., carbamazepine, phenytoin) significantly reduce perampanel levels; consider dose adjustment.
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
Take exactly as prescribed; do not stop abruptly as this may increase seizure frequency.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects are known.,Report any changes in mood, behavior, or suicidal thoughts to your healthcare provider immediately.,Use effective non-hormonal contraception during treatment and for 1 month after stopping, as perampanel reduces efficacy of hormonal contraceptives.,Avoid alcohol and other CNS depressants as they can worsen side effects.,Do not take with high-fat meals as they delay absorption; take on an empty stomach or with a light meal.,Store at room temperature away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
No interactions on record
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MERZEE vs ATROPINE AND DEMEROL, answered by our medical review team.
MERZEE is a Antihyperlipidemic (Cholesterol Absorption Inhibitor) that works by MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.. ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MERZEE and ATROPINE AND DEMEROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MERZEE is: 300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.. The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MERZEE and ATROPINE AND DEMEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MERZEE is classified as Category C. Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimester. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.